Featured Article

Where is RBQM Heading in The Future With AI?

Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials. With experience at both CluePoints and Veeva, Young discusses AI’s role, transparency, and the future of risk management in clinical trials.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Blog
ICH E6(R3), Demystified Part 4: Informed Consent
  • From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...
Read More
Blog
Why RBQM Programs Stall: The Gap Between Insight and Action
  • Many organizations invest heavily in detection, analytics, dashboards, and centralized monitoring. Yet RBQM still stalls. The...
Read More
Blog
RBQM for the Mid-Market Explained
  • Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI